The February issue of The American Journal of Gastroenterology highlights new clinical science and reviews, including joint ACG-ASGE quality indicators for upper GI endoscopy, the first medication for the treatment of at-risk metabolic-associated steatohepatitis (MASH), and a digital gut-directed hypnotherapy program for irritable bowel syndrome (IBS). This month we also published articles on eosinophilic esophagitis, primary biliary cholangitis, inflammatory bowel disease, colorectal endoscopic submucosal dissection, and more.
Several articles are highlighted below and access to any articles from this issue, or past issues, is available upon request. The College is also able to connect members of the press with study authors or outside experts who can comment on the articles.
Quality Indicators for Upper GI Endoscopy
Yadlapati, et al.
In a joint update from ACG and the American Society for Gastrointestinal Endoscopy (ASGE), the authors provide recommendations for quality indicators in upper GI endoscopy, covering pre-procedure, intraprocedure, and post-procedure periods. Each recommendation is graded according to the quality of evidence, and new indicators were added, including thorough photo documentation across all esophagogastroduodenoscopies (EGDs).
Comparison of Digitally Delivered Gut-Directed Hypnotherapy Program With an Active Control for Irritable Bowel Syndrome
Anderson, et al.
In this randomized control trial, the authors compared the efficacy of a digitally delivered program with and without gut-directed hypnotherapy (GDH) for patients with IBS. They found that the GDH program achieved greater improvement in GI symptoms and quality of life, and provided an equitable alternative to face-to-face behavioral strategies.
Update on Newly Federal Drug Administration-Approved Drug, Resmetirom: A Practical Perspective
Sidney Barritt, IV, MD, MSCR, FACG & Jonathan G. Stine, MD, MSc
In this Red Section article, the authors discuss resmetirom, the first medication approved by the FDA for at-risk MASH. They cover the mechanism of action of the thyroid hormone β agonist, its safety and efficacy, and considerations for drug interactions, particularly for patients with cardiometabolic conditions.
About the American College of Gastroenterology
Founded in 1932, the American College of Gastroenterology (ACG) is an organization with an international membership of over 19,000 individuals from 86 countries. The College’s vision is to be the preeminent organization supporting health care professionals who provide compassionate, equitable, high-quality, state-of-the-art, and personalized care to promote digestive health. The mission of the College is to provide tools, services, and accelerate advances in patient care, education, research, advocacy, practice management, professional development and clinician wellness, enabling our members to improve patients’ digestive health and to build personally fulfilling careers that foster well-being, meaning and purpose. Follow ACG on X @AmCollegeGastro and learn more at www.gi.org.
